Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical delgocitinib for facial vitiligo
2025-523635-19-00Phase 2Authorised
- Sponsor
- Gentofte Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delgocitinib in Vitiligo, sponsored by Gentofte Hospital. Primary endpoint: Change in F-VASI from baseline to Week 24. Planned start Mar 2026; status: authorised.
02
Drugs
delgocitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-523635-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523635-19-00.